OncoMatch/Clinical Trials/NCT06358677
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors
Is NCT06358677 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Topical Tretinoin for metastatic solid tumor.
Treatment: Topical Tretinoin — The goal of this clinical trial is to learn if using topical tretinoin will help patients with solid tumors who are experiencing an acneiform rash as a side effect of their treatment. Researchers will compare the use of tretinoin on one side of the face to the use of a placebo on the other side of the face to see if there is an impact.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-EGFR agent
Exception: within 90 days of registration
Treatment with an anti-EGFR agent within 90 days of registration.
Lab requirements
Liver function
Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN); AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN; Participants with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN.
Adequate organ function as defined as: Hepatic: Total Bilirubin ≤ 1.5x institutional upper limit of normal (ULN); AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN; Participants with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Huntsman Cancer Institute at University of Utah · Salt Lake City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify